BMY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedNo phase registeredNCT07465029A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in SpainBristol-Myers Squibb · Lower-risk Myelodysplastic Syndromes (TD LR-MDS)Active, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Apr 23, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03989414A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination...Celgene · Multiple MyelomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04099251Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaBristol-Myers Squibb · MelanomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Jun 28, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT04735978Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursReplimune, Inc. · Advanced Solid TumorActive, not recruitingREPLLeadBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05215470CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer ImmunotherapyHospital das Clínicas de Ribeirão Preto · Renal Cancer MetastaticActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 30, 2024Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT05688475A Rollover Study of CC-122Bristol-Myers Squibb · Non-Hodgkin LymphomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05853575Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Mirati Therapeutics Inc. · Advanced CancerActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Oct 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06146660A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · Obstructive Hypertrophic CardiomyopathyRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06870617Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)Abramson Cancer Center at Penn Medicine · Geriatric AssessmentActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06923891An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia PatientsVanguard Research Group · SchizophreniaNot yet recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Oct 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07681076Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersKaruna Therapeutics, Inc., a Bristol Myers Squibb company · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT00248287PhII ICb With/Without Erbitux in MBC PtsUS Oncology Research · Metastatic Breast CancerActive, not recruitingBMYCollaboratorPFECollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT00378105Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple MyelomaDana-Farber Cancer Institute · Multiple MyelomaActive, not recruitingTAKCollaboratorBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 2009Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT00825929Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.Radboud University Medical Center · HIV Infections
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT01054196Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 /...Weill Medical College of Cornell University · Multiple MyelomaActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Oct 2021Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT01208662Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65Paul Richardson, MD · Multiple MyelomaActive, not recruitingTAKCollaboratorBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 2022Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT02523040Lenalidomide for Adult Histiocyte DisordersDana-Farber Cancer Institute · Langerhans Cell Histiocytosis (LCH)Active, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 2024Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02544308Trial of Immunomodulatory Therapy in High Risk Solitary Bone PlasmacytomaUniversity College, London · PlasmacytomaActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Apr 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT02632305A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract CancerAHS Cancer Control Alberta · Unresectable Biliary Tract CancerActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT02812524Ipilimumab for Head and Neck Cancer PatientsProvidence Health & Services · Squamous Cell Carcinoma of the Head and NeckActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Sep 21, 2019Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT02919683Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityDana-Farber Cancer Institute · Head and Neck CancerActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 2019Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03355976BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasBrown University · Ovarian CancerActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Oct 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT03650894Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsProvidence Health & Services · Breast Neoplasm FemaleActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Mar 10, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT04674683Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced MelanomaHUYABIO International, LLC. · Unresectable or Metastatic MelanomaActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04933903BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabBrown University · Non Small Cell Lung CancerRecruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Oct 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 42 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.